Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

STE vs EW: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EW Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)

EW Overall Winner 6-Pillar Tally: STE 2 – 4 EW Matrix Metrics: STE 3 – 7 EW

As of Nov 16, 2026, Edwards Lifesciences Corp (EW) is the stronger overall head-to-head candidate over STERIS plc (STE) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). STE carries a Unified Composite Score of 28.1/100 (SELL) at $263.07 (23.9x Forward P/E, 19.2% operating margin), whereas EW carries 31.5/100 (SELL) at $106.66 (31.6x Forward P/E, 28.8% operating margin).

  • Defensive Composite Rating Caution: Although EW compares more favorably head-to-head, both STE (28.1/100 SELL) and EW (31.5/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About STE vs EW
STE NYSE
STERIS plc
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$263.07
-0.47% 1D
Market Cap $24.6B
TTM Revenue $6.17B
Forward P/E 23.9x
Beta / 30D Vol 0.20β · 37% Vol
Unified Composite Score
28.1 / 100 SELL
Tech 50.0 Fund 33.0 Flow 56.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 76
RSI-14: 75.8 · SMA20: $241.47 · SMA50: $224.07
EW NYSE Head-to-Head Winner
Edwards Lifesciences Corp
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$106.66
-0.46% 1D
Market Cap $60.8B
TTM Revenue $6.67B
Forward P/E 31.6x
Beta / 30D Vol 0.44β · 24% Vol
Unified Composite Score
31.5 / 100 SELL
Tech 50.0 Fund 29.0 Flow 51.0 Mom 44.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.7% over 20 days), RSI 79
RSI-14: 79.4 · SMA20: $97.03 · SMA50: $90.77

6-Pillar Scorecard Institutional Category Breakdown (STE 2 – 4 EW)

Columns: Metric · STE · EW
1. Valuation Multiples STE
Forward P/E 23.9x 31.6x
Trailing P/E 30.4x 61.5x
PEG Ratio 2.50x 2.33x
EV / Revenue 4.2x 8.8x
2. Growth & Scale EW
Revenue Growth (YoY) +8.8% +10.5%
Earnings Growth (YoY) +12.9% +6.7%
TTM Revenue (USD) $6.17B $6.67B
Market Cap $24.6B $60.8B
3. Profitability & Quality EW
Gross Margin 44.3% 78.0%
Operating Margin 19.2% 28.8%
Net Profit Margin 13.4% 15.3%
Return on Equity (ROE) 11.6% 9.3%
4. Balance Sheet & Cash Flow EW
Cash Generation (TTM) $937M $1.42B
Cash Flow Margin 15.2% 21.3%
Net Cash / Leverage $1.52B Net Debt (0.28x D/E) $2.41B Net Cash
Dividend Yield 1.01% None (0.00%)
5. Options & Positioning STE
Options Structure Phase SURGE UNCLASSIFIED
Current IV / %ile 32.2% (7th %ile) 24.6% (34th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat EW
OpEx & R&D Intensity 25.1% of Rev ($1.55B) 49.2% of Rev ($3.28B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Scale & Operating Efficiency Moat
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: STE (3) vs EW (7)
Institutional Metric STE EW Criterion Row Edge
Market Capitalization
Scale
$24.6B $60.8B Larger Scale EW
Trailing P/E Ratio
Valuation
30.4x 61.5x Lower Multiple STE
Forward P/E Ratio
Valuation
23.9x 31.6x Lower Multiple STE
Revenue Growth (YoY)
Growth
+8.8% +10.5% Higher Growth EW
Operating Margin (TTM)
Profitability
19.2% 28.8% Higher Margin EW
Net Profit Margin
Profitability
13.4% 15.3% Higher Margin EW
Return on Equity (ROE)
Capital Efficiency
11.6% 9.3% Higher ROE STE
52-Week Range Position
Momentum
91% ($195–$269) 96% ($75–$108) Stronger Trend EW
Beta / 30D Volatility
Risk Regime
0.20β · 37% Vol 0.44β · 24% Vol Lower Realized Risk EW
Unified Institutional Score
Composite Signal
28.1 / 100 (SELL) 31.5 / 100 (SELL) Higher Composite EW
Trailing 12M Revenue (USD)
Operating Scale
$6.17B $6.67B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
44.3% 78.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.50x PEG · 4.2x EV/Rev 2.33x PEG · 8.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$937M ($1.52B Net Debt (0.28x D/E)) $1.42B ($2.41B Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EW +5.01 pp
STE: +18.15% · EW: +23.16%
3M Horizon EW +4.03 pp
STE: +13.2% · EW: +17.23%
6M Horizon EW +5.87 pp
STE: +23.58% · EW: +29.45%
1Y Horizon EW +22.85 pp
STE: +1.01% · EW: +23.86%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period STE Revenue EW Revenue STE Op. Margin EW Op. Margin Margin Leader
FY2019 $2.78B $4.35B 14.8% 26.4% EW
FY2020 $3.03B $4.39B 17.7% 20.5% EW
FY2021 $3.11B $5.23B 17.6% 32.3% EW
FY2022 $4.22B $4.46B 11.3% 33.6% EW
FY2023 $4.54B $5.01B 17.4% 26.1% EW
FY2024 $5.14B $5.44B 16.3% 25.3% EW
FY2025 $5.46B $6.07B 15.9% 20.8% EW
FY2026 $5.94B N/A 18.6% N/A STE

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
STE SURGE
5d in phase · OBV ACCUMULATION
Current IV 32.2%
IV Percentile 7th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact STE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EW UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 24.6%
IV Percentile 34th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EW Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
STE Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $24.6B market capitalization and 19.2% operating margin.
OpEx & R&D Reinvestment 25.1% of Rev ($1.55B)
90D Engineering Disclosures 0 Published
EW Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $60.8B market capitalization and 28.8% operating margin.
OpEx & R&D Reinvestment 49.2% of Rev ($3.28B)
90D Engineering Disclosures 0 Published

Investor FAQ STE vs EW Key Questions & Quantitative Answers

As of Nov 16, 2026, Edwards Lifesciences Corp (EW) is the stronger overall head-to-head candidate over STERIS plc (STE) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). STE carries a Unified Composite Score of 28.1/100 (SELL) at $263.07 (23.9x Forward P/E, 19.2% operating margin), whereas EW carries 31.5/100 (SELL) at $106.66 (31.6x Forward P/E, 28.8% operating margin). Defensive Composite Rating Caution: Although EW compares more favorably head-to-head, both STE (28.1/100 SELL) and EW (31.5/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

EW leads the Growth & Scale pillar: STE posts +8.8% YoY revenue growth and +12.9% YoY earnings growth on $6.17B TTM revenue (44.3% gross margin, 19.2% operating margin), compared with EW at +10.5% YoY revenue growth and +6.7% YoY earnings growth on $6.67B TTM revenue (78.0% gross margin, 28.8% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), STE cumulative revenue shifted +113.7% while EW shifted +39.5%. In operating R&D and SG&A reinvestment, STE deploys 25.1% of Rev ($1.55B) (0 90-day corporate R&D disclosures) versus 49.2% of Rev ($3.28B) (0 disclosures) for EW.

STE screens cheaper on headline valuation multiples. STE trades at 23.9x Forward P/E, 30.4x Trailing P/E, 2.50x PEG, and 4.2x EV/Revenue (15.2% FCF margin), whereas EW trades at 31.6x Forward P/E, 61.5x Trailing P/E, 2.33x PEG, and 8.8x EV/Revenue (21.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against STE (11.6% ROE) versus EW (9.3% ROE) capital efficiency.

In options market volatility and institutional positioning, STE carries 32.2% implied volatility (7th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (0.20β · 37% Vol realized risk). By comparison, EW carries 24.6% implied volatility (34th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.44β · 24% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.